| David Hornickle, MD | |
|
346 Main St, Oley, PA 19547-8712 | |
| (610) 987-9870 | |
| (610) 987-0029 |
| Full Name | David Hornickle |
|---|---|
| Gender | Male |
| Speciality | |
| Experience | Years |
| Location | 346 Main St, Oley, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1821089269 | NPI | - | NPPES |
| 100901959 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD422611 (Pennsylvania) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| David Hornickle, MD 346 Main St, Oley, PA 19547-8712 Ph: (610) 987-9870 | David Hornickle, MD 346 Main St, Oley, PA 19547-8712 Ph: (610) 987-9870 |
News Archive
Sanovas, Inc., a life science technology company focused on developing and commercializing the next-generation of micro-invasive diagnostics, devices and drug delivery technologies, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the company's nested balloon catheter for localized drug delivery, a component of Sanovas' Vas Zeppelin Smart Catheter technology portfolio.
Cholesterol gets lots of bad press, and for good reason. An estimated 24 million women and 18 million men have total cholesterol levels of 240 milligrams per deciliter (mg/dL) or higher increasing their risk of heart attack and stroke.
Salix Pharmaceuticals, Ltd. today announced that as of September 30, 2009 Lupin Ltd. granted Salix the exclusive right in the United States to its bioadhesive drug delivery technology for use with rifaximin. Salix and Lupin have entered into a development, commercialization and license agreement under which the two companies will collaborate in the development and commercialization of a product incorporating rifaximin and utilizing Lupin's proprietary technology.
Celera Corporation today announced that it has signed a Declaration of Conformity and applied the CE mark to a real-time PCR (polymerase chain reaction) test for detection of a variant in the KIF6 gene, allowing the test to be marketed in the European Union and other geographic areas that recognize the CE Mark.
› Verified 5 days ago
Dr. Jeffrey A Gold, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2866 W Philadelphia Ave, Oley, PA 19547 Phone: 610-987-3451 Fax: 610-987-6809 |